Top Stories
-
A new drug that penetrates the protective barrier around pancreatic cancers and accumulates in malignant cells may improve current chemotherapy, a study in mice suggests.
-
Researchers in Columbia's medical and engineering schools have edited a strain of non-pathogenic bacteria to colonize solid tumors in mice and safely deliver potent immunotherapies.
-
Barring ovarian cancer surgery at low-volume hospitals could limit access to care for many rural and underserved patients, a new study has found.
Topic
-
At Columbia, patients with brain cancer will be able to participate in a new type of clinical trial that promises to speed up the development of better drugs for glioblastoma.
Topic
Latest News
- October 28, 2015
Columbia has one of six new sites launched by the NIH's Breast Cancer and Environment Research Program for prevention and research across the lifespan.
Topic
- October 26, 2015
Dr. Andrea Califano has won a two-year $200,000 research grant for neuroendocrine cancer research.
Topic
- October 21, 2015
According to a recent study, a microsurgical approach is found to be a safe and effective technique to prevent breast cancer-related lymphedema.
Topic
- October 12, 2015
Andrea Califano and his investigative team discover a molecular signaling mechanism underlying a specific type of highly aggressive breast cancer.
Topic
- October 5, 2015
KEYTRUDA is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.
Topic
- September 23, 2015
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
Topic
- September 18, 2015
Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.
Topic
- May 26, 2015
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.
- April 14, 2015
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.
- March 26, 2015
Nearly 50 years after the “war on cancer” was declared in the United States, precision medicine is changing the face of cancer research.
Topic
